Company intelligence / Profile preview

Mecwins

Tres Cantos, Community of Madrid, Spainmecwins.com ↗

Ownership: Private
Development stage: Commercial

Overview

Mecwins has developed an ultrasensitive diagnostic platform capable of detecting protein biomarkers at concentrations several orders of magnitude lower than conventional methods. Their AVAC Analyzer enables high-throughput multiplexed analysis for oncology, cardiology, infectious disease, neurology, and inflammation. The company collaborates with academic institutions and R&D centers globally to advance biomarker discovery and diagnostics innovation.

Therapeutic areas: OncologyImmunologyCardiovascularNeurologyInfectious Diseases
Modalities: Device (diagnostic instrumentation)Immunoassay (ultrasensitive digital immunoassays)Nanoparticle-based technology
Industry: Protein Biomarker Diagnostics

Partnerships

Collaborates with universities/research institutes globallyIMB-CNM-CSIC

Beyond the preview

Go deeper on Mecwins.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mecwins.

Explore the full profile